1-(bis(4-fluorophenyl)methyl)piperazine
Suppliers
Names
[ CAS No. ]:
27469-60-9
[ Name ]:
1-(bis(4-fluorophenyl)methyl)piperazine
[Synonym ]:
N-[bis(4-fluorophenyl)methyl]piperazine
1-(4,4'-Difluorodiphenylmethyl)piperazine
4,4'-Difluorobenzhydrylpiperazine
1-[Bis-(4-fluorophenyl)methyl]piperazine
1-[(4',4''-difluorodiphenyl)methyl]piperazine
MFCD00038660
1 [bis(4-Fluorophenyl)methyl]-piperazine
1-[Bis(4-fluorophenyl)methyl]piperazine
1-(4,4'-Difluorobenzhydryl)piperazine
1-(bis(4-fluorophenyl)methyl)piperazine
[bis(4-fluorophenyl)methyl]piperazine
1-Bis(4-fluorophenyl)methyl piperazine
Piperazine, 1-[bis(4-fluorophenyl)methyl]-
1-[bis-(p-fluorophenyl)methyl]piperazine
EINECS 248-476-0
Chemical & Physical Properties
[ Density]:
1.2±0.1 g/cm3
[ Boiling Point ]:
367.9±37.0 °C at 760 mmHg
[ Melting Point ]:
88-92 °C(lit.)
[ Molecular Formula ]:
C17H18F2N2
[ Molecular Weight ]:
288.335
[ Flash Point ]:
176.3±26.5 °C
[ Exact Mass ]:
288.143799
[ PSA ]:
15.27000
[ LogP ]:
2.95
[ Vapour Pressure ]:
0.0±0.8 mmHg at 25°C
[ Index of Refraction ]:
1.560
[ Water Solubility ]:
0.34 g/L (20 ºC)
MSDS
Safety Information
[ Symbol ]:
GHS06
[ Signal Word ]:
Danger
[ Hazard Statements ]:
H301-H315-H319-H335
[ Precautionary Statements ]:
P261-P301 + P310-P305 + P351 + P338
[ Personal Protective Equipment ]:
Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges
[ Hazard Codes ]:
T:Toxic
[ Risk Phrases ]:
R25;R36/37/38
[ Safety Phrases ]:
S26-S45-S36/37/39
[ RIDADR ]:
UN 2811 6.1/PG 3
[ WGK Germany ]:
3
[ Packaging Group ]:
I; II; III
[ Hazard Class ]:
6.1
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Articles
Res. Commun. Chem. Pathol. Pharmacol. 78(1) , 85-95, (1992)
The oxidative metabolism of flunarizine [1-[bis(4-fluorophenyl)-methyl]-4-(3-phenyl-2-propenyl)piperazine, FZ] to 1-[bis-(4-fluorophenyl)methyl]piperazine (M-1), 1-[bis(4-fluorophenyl)methyl]-4-[3-(4'...
Arch. Toxicol. 69(6) , 391-6, (1995)
Toxic effects of a detriazinyl metabolite of almitrine (DTMA) were evaluated in rats and on cultured rat macrophages. In rats daily treated with DTMA for 16 weeks, spastic gaits with heel-lifting appe...